Paradigm Biocapital Advisors LP — VAXCYTE INC PCVX: Quarterly 13F Position History
Paradigm Biocapital Advisors LP has reported VAXCYTE INC (PCVX) on 9 13F-HR filings in Pactolio's tracked window, first appearing in Q1 2024. As of Q1 2026, the position is sized at 4,793,020 shares ($278.5M market value, 5.69% of the equity book). Quarter-over-quarter share count change: + 725,000 (+17.8%) .
- 4,793,020Shares Held (Latest Filing)
- $278.5MReported Market Value (Latest Filing)
- 5.69%Portfolio Weight (% of 13F Equity Book)
- +725,000Quarter-over-Quarter Share Change
- +$90.8MQuarter-over-Quarter Value Change
- 4,793,020Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 9 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 4,793,020 | +725,000 | +17.8% | $278.5M | 5.69% | $58.11 |
| Q4 2025 | 4,068,020 | +283,265 | +7.5% | $187.7M | 5.03% | $46.14 |
| Q3 2025 | 3,784,755 | +411,918 | +12.2% | $136.3M | 4.03% | $36.02 |
| Q2 2025 | 3,372,837 | +1,676,356 | +98.8% | $109.7M | 4.68% | $32.51 |
| Q1 2025 | 1,696,481 | +273,694 | +19.2% | $64.1M | 2.95% | $37.76 |
| Q4 2024 | 1,422,787 | +795,055 | +126.7% | $116.5M | 4.05% | $81.86 |
| Q3 2024 | 627,732 | +530 | +0.1% | $71.7M | 2.51% | $114.27 |
| Q2 2024 | 627,202 | 612,793 | -49.4% | $47.4M | 1.81% | $75.51 |
| Q1 2024 | 1,239,995 | — | — | $84.7M | 2.98% | $68.31 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Paradigm Biocapital Advisors LP first disclose a PCVX position in 13F-HR filings?
Paradigm Biocapital Advisors LP first reported VAXCYTE INC (PCVX) on its 13F-HR filing for the period ending 2024-03-31 (Q1 2024). The position has appeared on 9 reported quarters within Pactolio's tracked window.
What was Paradigm Biocapital Advisors LP's most recent quarter-over-quarter share-count change in PCVX?
Between Q4 2025 and Q1 2026, Paradigm Biocapital Advisors LP added 725,000 shares of PCVX (+17.8%), bringing the total reported position to 4,793,020 shares at a market value of $278.5M.
Does the implied price-per-share represent Paradigm Biocapital Advisors LP's cost basis in PCVX?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.